Adherium appoints Dawn Bitz as Chief Executive Officer
Adherium appoints Dawn Bitz as Chief Executive Officer
Melbourne, Australia – 22 July 2025: Leading digital health company Adherium Limited (ASX:ADR), has today announced the appointment of Dawn Bitz as Chief Executive Officer (CEO), effective immediately.
Ms. Bitz, based in the United States, brings nearly three decades of transformational leadership experience in the global medical device and digital health industries, with a proven track record of scaling businesses from concept through global commercialisation.
Adherium Chairman, Mr. Lou Panaccio, said:
“On behalf of the Board, our team, shareholders, and partners, I am delighted to welcome Dawn Bitz as our new CEO. Dawn is a dynamic, results-driven executive with deep expertise in respiratory care, clinical innovation, and global market strategy. Her passion for improving respiratory patient outcomes, coupled with her remarkable record of building high-performance teams and delivering bold growth, makes her the ideal leader for Adherium. We are primed to expand the reach and impact of Hailie® technology at scale – working closely with world-class key opinion leading clincians in the US, UK and AU, and with an experienced commercial team at the helm.”
In accepting the appointment, Ms. Bitz said:
“I am honored and thrilled to lead Adherium at this exciting stage of its journey. The Company has a powerful portfolio of clinically proven technologies, an exceptional team, and a clear opportunity to transform respiratory care globally. Together, we will accelerate innovation, expand access, and deliver meaningful value to patients, providers, and health systems worldwide. Together, we will continue to build a sustainable model of care, which leverages the power of technology to drive proactive and preventive clinical intervention for people living with respiratory illness – a gold standard, which improves and even saves lives.”
Following a global executive search conducted Bartholomew Advisors, Ms. Bitz joins Adherium with extensive experience leading multi-segment, global P&Ls up to $500M+, overseeing M&A transactions totalling hundreds of millions of dollars, and securing substantial funding through a combination of federal and state grants and equity financing. She has successfully launched multiple medical technologies and lead product lines with revenues ranging from $25M to $150M; led regulatory and clinical strategies across PMA, 510(k), and De Novo pathways; and built scalable
commercial platforms in critical care, respiratory, and digital health markets.
Read the full ASX release here: https://bit.ly/ADR_New_CEO